Neurovascular Embolization Devices

Global Neurovascular Embolization Devices Market to Reach US$1.5 Billion by 2030

The global market for Neurovascular Embolization Devices estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Embolic Coils, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$579.6 Million by the end of the analysis period. Growth in the Flow Diversion Devices segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$315.4 Million While China is Forecast to Grow at 7.1% CAGR

The Neurovascular Embolization Devices market in the U.S. is estimated at US$315.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$294.0 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Neurovascular Embolization Devices Market – Key Trends & Drivers Summarized

Why Are Neurovascular Embolization Devices Essential in Stroke and Aneurysm Treatment?

Neurovascular embolization devices have become critical in the management of intracranial aneurysms, arteriovenous malformations (AVMs), and other cerebrovascular abnormalities. These minimally invasive devices, including embolic coils, liquid embolic agents, flow diverters, and vascular plugs, are designed to prevent aneurysm rupture, reduce blood flow to abnormal vessels, and stabilize cerebral circulation. With stroke and hemorrhagic conditions being leading causes of disability and mortality worldwide, neurovascular embolization procedures are gaining traction as an effective alternative to traditional surgical interventions such as craniotomy and clipping. The advancement of endovascular techniques has significantly improved patient outcomes, reducing recovery times and post-procedural complications. In particular, flow diverters have emerged as a game-changing technology for treating wide-necked and complex aneurysms that were previously considered inoperable. Additionally, liquid embolic agents are revolutionizing AVM treatment by allowing precise vessel occlusion, reducing the risk of recurrent hemorrhage. As the global burden of neurovascular diseases rises, the demand for embolization devices is increasing, driving further innovation and adoption in neurointerventional procedures.

What Challenges Are Hindering the Adoption of Neurovascular Embolization Devices?

Despite their proven efficacy, several challenges hinder the widespread adoption of neurovascular embolization devices. One of the primary concerns is the high cost of endovascular embolization procedures, making them less accessible in regions with limited healthcare funding. Additionally, the technical complexity of embolization procedures requires highly trained neurointerventionalists, limiting availability in rural and underdeveloped healthcare systems. Another significant challenge is the risk of procedural complications, including vessel perforation, ischemia, and migration of embolic materials, which can lead to stroke or neurological deficits. The variability in patient anatomy and vascular conditions also necessitates personalized treatment planning, requiring advanced imaging and extensive pre-procedural evaluation. Regulatory hurdles and long approval cycles for new embolization technologies further slow down market expansion, delaying access to next-generation neurovascular treatments. Moreover, patient awareness about minimally invasive neurovascular interventions remains low, leading to delayed diagnosis and underutilization of embolization therapies. Addressing these challenges will require greater investment in physician training, improvements in device safety and precision, and increased efforts to make embolization procedures more widely available and affordable.

How Are Innovations Enhancing the Effectiveness of Neurovascular Embolization Devices?

The field of neurovascular embolization is witnessing rapid technological advancements that are improving procedural success rates and expanding treatment options for complex cerebrovascular conditions. One of the most significant innovations is the development of bioactive embolic coils, which promote faster aneurysm occlusion and long-term vessel healing by encouraging endothelial cell growth. Additionally, the introduction of second-generation flow diverters with improved flexibility and flow modulation capabilities is enhancing treatment safety and effectiveness for large and wide-necked aneurysms. The integration of AI-powered imaging and robotic-assisted endovascular navigation is enabling precise embolization procedures, minimizing the risk of complications and improving patient outcomes. Liquid embolic agents with enhanced viscosity control are also advancing AVM treatment by providing better penetration and adhesion to targeted vascular structures. Moreover, the emergence of combination therapies—such as embolization followed by neuroprotective pharmacological interventions—is further optimizing neurovascular treatment strategies. As device manufacturers continue to refine embolization technologies, neurointerventional procedures are becoming safer, more efficient, and accessible to a broader patient population.

What Is Driving the Growth of the Neurovascular Embolization Devices Market?

The growth in the neurovascular embolization devices market is driven by several factors, including the rising prevalence of cerebrovascular diseases, increasing adoption of minimally invasive procedures, and continuous advancements in endovascular technology. The growing incidence of intracranial aneurysms and AVMs, fueled by aging populations and lifestyle-related risk factors such as hypertension and smoking, is creating a strong demand for effective neurovascular interventions. The shift toward minimally invasive techniques is further accelerating market expansion, as embolization procedures offer lower morbidity and shorter hospital stays compared to open surgeries. Technological advancements in embolization materials, including bioresorbable and radiopaque embolic agents, are enhancing procedural precision and safety. Additionally, the increasing availability of advanced neuroimaging techniques, such as 3D rotational angiography and perfusion MRI, is improving diagnosis and treatment planning, driving higher adoption rates. Expanding reimbursement policies and government initiatives aimed at improving stroke care infrastructure are also playing a crucial role in market growth. As healthcare providers and research institutions continue to invest in neurovascular innovation, the neurovascular embolization devices market is poised for substantial expansion, offering life-saving solutions for patients with complex cerebrovascular conditions.

SCOPE OF STUDY:

The report analyzes the Neurovascular Embolization Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Embolic Coils, Flow Diversion Devices, Liquid Embolic Agents, Aneurysm Clips); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Abbott Laboratories
• Acandis GmbH
• ASAHI INTECC CO., LTD.
• B. Braun Melsungen AG
• Balt SAS
• Cerus Endovascular
• Imperative Care
• Integer Holdings Corporation
• Integra LifeSciences Corporation
• Johnson & Johnson Services, Inc. (CERENOVUS)
• Medikit Co., Ltd.
• Medtronic plc
• Merit Medical Systems, Inc.
• MicroPort Scientific Corporation
• MicroVention, Inc. (Terumo Corporation)
• Penumbra, Inc.
• Perflow Medical Ltd.
• Phenox GmbH
• Shape Memory Medical
• Stryker Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.